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Balloon, Stents, Drugs, Drills,
and Treadmills
Are We Closer to the Optimal Algorithm?*Michael R. Jaff, DOSEE PAGE 1105O n the one hand, we may all be enthusiastic.For decades, physicians, regulators, reim-bursement policymakers, and patients
have hoped that the level of evidence guiding the
treatment of peripheral artery disease (PAD) would
improve from single-center, retrospective, “this is
how I do it” papers and prospective single-arm regis-
tries to randomized clinical trials. In fact, with the
publication of the ﬁrst randomized trial of drug-
eluting stents for the treatment of femoropopliteal
PAD, we welcomed a new era in technology and evi-
dence (1). Although several critics wondered whether
the conclusions drawn from the Zilver PTX (Zilver PTX
Randomized Controlled Trial of Paclitaxel-Eluting
Stents for Femoropopliteal Disease) study were rele-
vant to modern clinical practice, because the compar-
ator arm was percutaneous transluminal angioplasty,
a treatment used with less frequency by intervention-
ists, the Zilver PTX study raised the proverbial bar of
evidence expected by interested parties.
Subsequently, a large-scale, prospective, multicenter
randomized trial of a novel paclitaxel-coated angio-
plasty balloon catheter compared with an uncoated*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
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Massachusetts General Physicians Organization.angioplasty catheter ushered in the era of non–stent-
based drug–device combination products (2).
With this increase in levels of evidence, it appears
that drug–device combination therapy has emerged
as a major endovascular strategy for infrainguinal
PAD. In this issue of JACC: Cardiovascular Inter-
ventions, a multicenter, prospective outcomes regis-
try from well-respected investigators from Japan (the
ZEPHYR study [Zilver PTX for the Femoral Artery and
Proximal Popliteal Artery]) has added to our knowl-
edge base, providing predictors of restenosis (3).
Across multiple centers in Japan, 690 patients with
intermittent claudication or critical limb ischemia
were treated with the Zilver PTX stent (Cook Medical,
Bloomington, Indiana). Investigators were encour-
aged to perform intravascular ultrasound (IVUS)
assessment of the target lesion before and after
intervention, and patients were followed with either
angiography or noninvasive arterial duplex ultraso-
nography for 1 year following intervention. Perhapsof greatest importance of these data is the “real-
world” nature of the patients enrolled in this multi-
center registry. The mean lesion length in the Zilver
PTX randomized trial ranged from 63.1 to 66.4 mm. In
the current ZEPHYR study, the mean lesion length
was 167 mm.
The restenosis rate with the Zilver PTX stent was
37% in this series, greater than the 16.9% restenosis
rate of the Zilver PTX arm of the randomized trial. Of
those patients who completed follow-up, lesion
lengths longer than 160 mm and smaller diameters of
the treated segments (as measured by IVUS) were
predictors of restenosis. In fact, the primary patency
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1114of patients without predictors of restenosis was 85%,
but if 2 or more risk factors were evident, the primary
patency dropped to 49%.
Although these 2 results are quite different, one
reason is self-evident: the patients in the ZEPHYR
registry were more complex than those included in
the randomized trial. Lesion lengths are longer, and
one-third of patients presented with critical limb
ischemia (CLI), whereas only 8.5% to 8.9% of patients
in the randomized trial had CLI.
The major limitation of the ZEPHYR study includes
the lack of a prospective comparator arm, preventing
the ability to compare, head-to-head, the results
of the randomized trial to this registry. Of similar
importance, interpretation of the IVUS and follow-up
duplex ultrasonography images were performed by
the site investigators rather than having them inter-
preted by a central reading laboratory. In the recent
Peripheral Academic Research Consortium (PARC)
publication (4), broad representation by physician
and regulatory experts from the United States and
Japan clearly stated that independent adjudication of
images be performed in clinical trials.
Given these data, combined with more recent data
emerging about the treatment of symptomatic PAD,
excitement must be tempered by the lack of
comparative device data. Physicians managing pa-
tients with PAD have no reliable data demonstrating
outcomes comparing a drug-eluting stent to a drug-
coated balloon. With the ever-increasing interest in
cost of care, we have no objective data supporting
comparative effectiveness leading to appropriate
decision making with modern medical devices. The
limited cost-effectiveness data are largely modeled
on the basis of previously published data with a series
of “suppositions,” falling short of allowing appro-
priate value-based decisions.Comparisons of various endovascular devices, both
to each other (5) and to surgery, speciﬁcally in patients
with CLI (6), are emerging, but until we have the re-
sults, the pressure by hospital groups, purchasing
agencies, payers, and regulators to decide what stra-
tegies are appropriate for patients represent real
threats. It is the physician who possesses the experi-
ence, skill, and capabilities that are best suited to
determine optimal treatment. Cost pressures muddy
the waters of decision making, particularly without
objective cost-effectiveness data, and economic
models only carry the debate so far. In addition, the
comparison of endovascular or surgical revasculariza-
tion to exercise training, considered by some as the
most cost-effective treatment, remains confusing.
Recent publication of the CLEVER (Claudication: Ex-
ercise Versus Endoluminal Revascularization) trial 6-
month data (7) suggested that supervised exercise
therapy is more effective than endovascular revascu-
larization for aortoiliac PAD. The 18-month data,
however, demonstrate that any initial advantage of
exercise therapy over stent revascularization is lost (8).
Until we have a series of high-quality comparative
studies of different revascularization strategies for
patients with PAD, the elusive algorithm of care will be
relegated to opinion, conjecture, bias and margin
pressures—none of which really help our patients.
Adoption of the PARC (4) recommendations will at
least set a common bar for the organization and
implementation of these trials. Time is of the essence,
as our patients with PAD continue to suffer and die (9).
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